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This review examines the results of vasodilator therapy in 
patients with chronic regurgitant lesions of the aortic and mitral 
valves. The analysis includes those studies which provide data on 
hemodynamic measurements, left ventricular systolic function, 
ventricular volumes and regurgitant flow. In patients with chronic 
aortic or mitral regurgitation, the short-term administration 
of nitroprusside, hydralazine, nifedipine or an angiotensin- 
converting enzyme (ACE) inhibitor produces alutary hemody- 
namic effects. The major difference in the response to combined 
preload and afterload reduction (i.e., nitroprusside) in patients 
with aortic versus mitral regurgitation was that forward stroke 
volume generally increased and ejection fraction remained un- 
changed in mitral regurgitation, whereas ejection fraction gener- 
ally increased and forward stroke volume remained unchanged in
aortic regurgitation. These observations suggest that a reciprocal 
relation between regurgitant and forward flow characterizes the 
response to preload and afterload reduction in mitral regurgita- 
tion (through a preload-dependent dynamic regurgitant orifice), 
whereas correction of afterload mismatch dominates the response 
in aortic regurgitation. In studies of long.term vasodilator therapy 
in patients with chronic aortic regurgitation, a reduction in left 
ventricular volumes and regurgitant fraction, with or without an 
increase in ejection fraction, has been observed uring treatment 
with hydralazine, nifedipine and ACE inhibitors. Patients with the 
largest, sickest hearts generally benefit he most from treatment 
with vasoactive drugs. Nonetheless, favorable ventricular remod- 
eling has been reported in asymptomatic patients, and long-term 
nifedipine use has delayed the need for operation in asymptomatic 
patients with chronic aortic regurgitation. For patients with 
chronic mitral regurgitation, definition of the etiology of the lesion 
is a prerequisite for choosing appropriate therapy. Excluding 
patients with obstructive hypertrophic cardiomyopathy and mitral 
valve prolapse, and some with fixed-orifice (i.e., rheumatic) mitral 
regurgitation, the signal importance of preload reduction suggests 
that the preferred long-term therapy for symptomatic chronic 
mitrai regurgitation is an ACE inhibitor. There are no long-term 
studies that support the use of vasodilator therapy in asymptom- 
atic patients with chronic mitral regurgitation. 
(J Am Coil Cardiol 1996;28:1083-91) 
The time-honored medical therapy for chronic valvular egur- 
gitation has been to treat the major consequences of volume 
overload, namely, systolic dysfunction of the ventricle and 
congestive heart failure. For the most part, this therapy has 
been the same as that used for most patients with other causes 
of heart failure. During the past two decades, however, amore 
complete understanding of the specific ventricular loading 
conditions in aortic and mitral regurgitation and familiarity 
with a spectrum of vasoactive drugs have combined to provide 
the potential for altering hemodynamic abnormalities in regur- 
gitant valve disease. In this manner, it becomes possible to 
offer symptomatic relief and potentially delay the development 
ofventricular dysfunction and heart failure. Such strategies are 
targeted to reduce the volume of regurgitant flow and to 
achieve favorable remodeling of the ventricle. Implicit in the 
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latter is the goal of optimizing the loading conditions of the 
volume overloaded ventricle. To provide the rationale for 
effective medical therapy in patients with valvular regurgita- 
tion, it is appropriate to analyze the hemodynamic determi- 
nants of regurgitant flow and to examine the mechanisms by 
which ventricular remodeling may prove advantageous to the 
volume-overloaded heart. 
Determinants  o f  Regurg i tant  Flow 
The determinants of valvular egurgitation are best under- 
stood by examination of the variables of the orifice equation. 
This equation is based on the Torricelli principle, which states 
that turbulent flow through an orifice varies as the square root 
of the pressure gradient across that orifice (1). By solving the 
orifice equation for the regurgitant volume, one can directly 
examine the hydraulic determinants of regurgitant flow. This 
principle can be applied either to the aortic or mitral valve. 
Aortic Regurgitation 
The hydraulic determinants of aortic regurgitant volume 
are described by the following equation: 
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Abbreviations and Acronyms 
ACE - angiotensin-converting e zyme 
LV = left ventricular 
ARV = AROA × C × \,AOdm - LVdm × T~, 
where ARV = aortic regurgitant volume; AROA = aortic 
regurgitant orifice area; C = constant; AOdm = aortic dia- 
stolic mean pressure; LVdm = LV diastolic mean pressure; 
and T a = time or duration of diastole. In primary disease of 
the aortic valve, it has been assumed that regurgitant orifice 
area is constant, although this assumption may not be valid in 
some patients with disease of the aortic root. The duration of 
diastole is primarily a function of heart rate, and thus, as 
pointed out by Corrigan (2) 160 years ago, bradycardia will 
increase aortic regurgitant flow. Several investigators (3-6) 
have examined the effect of increasing heart rate as a means of 
reducing regurgitant flow. In these studies, increasing heart 
rate was uniformly associated with a decrease in regurgitant 
volume/beat, but in most instances regurgitant volume/minute 
remained unchanged. Of note, however, left ventricular (LV) 
end-diastolic pressure and volume decreased in response to 
pacing-induced tachycardia (5,6). Despite these observations, 
Firth et al. (6), conclude that "pacing induced tachycardia 
offers little, if any, potential benefit in the therapy of patients 
with aortic regurgitation." Thus, although long-term manipu- 
lations of heart rate have relatively little potential for signifi- 
cant benefit, clinicians should be alert to the danger of 
profound bradycardia n this condition. 
In addition to the regurgitant orifice area and heart rate, 
the other major determinant of regurgitant volume is the 
transvalvular p essure gradient throughout diastole. Although 
this variable provides a rationale for treating diastolic hyper- 
tension in aortic regurgitation, it should be recognized that 
most vasodilator therapies reduce the aortic diastolic pressure 
and LV diastolic pressure. As a result, there may be little 
change in the transvalvular pressure gradient. Moreover, the 
benefit of any reduction in pressure gradient is reduced by the 
square root sign in the orifice equation. Thus, a 25% reduction 
in the pressure gradient would be expected to reduce regurgi- 
tant volume by only 13%. Recently, it has been suggested (7) 
that in patients with aortic stenosis, valve resistance, calculated 
as the simple quotient of pressure gradient and flow per unit 
time, may more accurately reflect he hydraulics of a narrowed 
aortic valve than does the Torricelli principle. Cannon et al. 
(8), have demonstrated that such is the case in subjects with 
noncritical stenosis and small transaortic gradients, but 
whether this principle applies to the dynamics of aortic regur- 
gitant flow remains to be shown. 
The major determinants of aortic regurgitant volume are 
the regurgitant orifice area, the duration of diastole and the 
diastolic transvalvular pressure gradient. It should be noted 
that neither LV ejection fraction nor systemic vascular esis- 
tance are direct determinants of regurgitant volume. Thus, the 
notion that a greater forward stroke volume or a decrease in 
the regurgitant fraction means less regurgitant flow is not valid 
unless one of the variables of the orifice equation is altered. 
Consideration of these hydraulic principles places substan- 
tial constraints on the potential for achieving a meaningful 
reduction i  regurgitant volume in chronic aortic regurgitation. 
If, indeed, the aortic valve lesion is fixed or near fixed, 
nonsurgical methods have little potential to reduce the regur- 
gitant orifice size. Likewise, in the absence of diastolic hyper- 
tension, a steady state reduction in aortic diastolic pressure 
sufficient o reduce regurgitant volume significantly will be 
difficult to accomplish with vasodilator therapy, particularly 
because aortic regurgitation itself is generally associated with a 
low aortic diastolic pressure, and a further reduction may 
compromise the high requirements for myocardial blood flow 
of a hypertrophied left ventricle. These constraints suggest that 
if medical therapy is to be effective in the management of 
chronic aortic regurgitation, it is not likely to do so through the 
mechanism of a reduced regurgitant volume alone. 
Mitral Regurgitation 
The hydraulic determinants of mitral regurgitant volume 
are described by the following equation: 
MRV = MROA x C x ,d V~smsm - LAsm x T~, 
where MRV = mitral regurgitant volume; MROA = mitral 
regurgitant orifice area; C = constant; LVsm = LV systolic 
mean pressure; LAsm = left atrial systolic mean pressure; and 
Ts = time or duration of systole. Unlike chronic aortic 
regurgitation, the regurgitant orifice area in some forms of 
mitral regurgitation is dynamic and critically dependent on 
ventricular dimensions. This is of great importance inchoosing 
appropriate therapy, and it provides pecial opportunities for 
effective therapy in mitral regurgitation that are not applicable 
to patients with chronic aortic regurgitation. 
To examine the hydraulic determinants of regurgitant flow 
in mitral regurgitation, it is helpful to classify the etiology of 
the valve disease on the basis of whether the mitral regurgitant 
orifice is fixed or dynamic. The prototype of fixed orifice 
disease is the rheumatic lesion. Mitral regurgitation due to 
severe mitral annular calcification also falls into this category. 
In contrast, there are three conditions that characteristically 
exhibit wide variations in the severity of regurgitation that are 
closely coupled to changes in ventricular dimensions. For 
example, in patients with hypertrophic obstructive cardiomy- 
opathy or mitral valve prolapse, interventions or vasoactive 
drugs that reduce ventricular preload increase the severity of 
mitral regurgitation and indeed serve as useful provocative 
tests for the clinical identification of these conditions. In 
contrast, in patients with dynamic papillary muscle dysfunction 
often associated with acute coronary syndromes or dilated 
cardiomyopathy, these same interventions reduce the severity 
of the mitral regurgitation. I  such cases, the prompt reduction 
in regurgitant volume and often dramatic clinical improvement 
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seen with nitrate therapy is causally related to a decrease in 
ventricular volume. Experimental studies of acute mitral re- 
gurgitation using a canine model (9,10) have demonstrated 
convincing evidence of the dynamic nature of the mitral 
regurgitant orifice and its dependence on ventricular volume 
and contractile state. Thus, if one excludes patients with pure 
fixed orifice (i.e., rheumatic) disease and those with hypertro- 
phic cardiomyopathy or mitral valve prolapse, the importance 
of reducing ventricular size as a means of lessening regurgitant 
volume may have clinical utility, not only in cases of mitral 
regurgitation due to papillary muscle dysfunction but also in 
some patients with prosthetic valve dysfunction or ruptured 
chordae tendinae. 
As in patients with aortic regurgitation, the hemodynamic 
variables of the orifice equation offer ample reason for vigor- 
ous treatment of hypertension i  patients with mitral regurgi- 
tation. Furthermore, as demonstrated by Jose et al. (11), the 
increase in mitral regurgitation produced by elevated blood 
pressures i often more than can be predicted by an increase in 
the transvalvular pressure gradient alone and can only be 
explained by an increase in the regurgitant orifice area. Thus, 
in patients who do not have fixed-orifice mitral regurgitation, 
the benefit of lowering blood pressure may be unexpectedly 
gratifying and greater than that predicted by a reduction i  the 
transmittal systolic gradient alone. 
Ventricular Remodeling 
The potential for improving LV performance in chronic 
mitral and aortic regurgitation need not involve a change in the 
size of the regurgitant volume. Indeed, there is reason to 
suspect hat the long-term benefit of vasodilator therapy in 
chronic volume overload (particularly aortic regurgitation) 
may be independent of changes in regurgitant volume. A 
possible mechanism for this benefit is illustrated in Figure 1. 
Depicted are the acute and chronic effects of combined 
preload and afterload reduction in a hypothetical case. With 
short-term therapy, reduced fiber shortening associated with a 
decrease inpreload is offset by a reduction i  afterload and, as 
a result, the total stroke volume (forward plus regurgitant) is 
maintained. With long-term therapy and a gradual regression 
of hypertrophy as well as a leftward shift of the diastolic 
pressure-volume curve, the remodeled smaller ventricle func- 
tions much as it would have before dilation and expansive 
remodeling occurred. To some degree, preload reserve is 
reestablished, and a large total stroke volume is preserved by 
the continued unloading effect of vasodilator therapy. The 
effects of hypertrophy regression are also illustrated in Figure 
1. The essence of this long-term response is a reduction in 
ventricular volume and wall stress, which need not require a 
change in heart rate, contractile state or regurgitant flow. 
The proven benefit of ACE inhibitors or combined nonspe- 
cific vasodilator therapy in patients with heart failure (12-15) 
who do not have primary valvular egurgitation provides the 
framework for a similar effect in treating patients with chronic 
aortic or mitral regurgitation. If, indeed, reductions in wall 
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Figure 1. Effects of combined preload and aflerload reduction on 
pressure-volume relations (upper panel) and stress-volume/mass re- 
lations (lower panel). Upper panel, Loop A represents the baseline 
state in a hypothetical patient with chronic aortic regurgitation. Loop 
B illustrates the acute ffects of combined preload and afterload 
reduction; the negative heterometric effect of a decrease in preload is
countered by' a reduction i afterload, and stroke volume isunchanged. 
Loop C represents the results of long-term vasodilator therapy; the 
pressure-volume curve of the remodeled, smaller ventricle has shifted 
upward and to the left of that seen in the baseline (loop A) and acute 
(loop B) states; ejection fraction (EF) and stroke volume are main- 
tained. Lower panel, The effect of regression fhypertrophy induced 
by chronic vasodilator therapy is shown by examining the stress- 
volume/mass relations. With regression f hypertrophy, the remodeled 
smaller ventricle (loop C) exhibits higher end-diastolic and end-systolic 
volume/mass ratios and higher systolic stress than are seen after acute 
load reduction (loop B), but still less than in the baseline state (loop A). 
stress are closely coupled to the improvement observed in 
patients with congestive heart failure treated with vasodilators, 
it should be possible to predict responsiveness from baseline 
characteristics. For example, a reduced contractile state, 
graphically represented by a decrease in the slope of the 
systolic pressure-volume r lation, would permit a greater 
increase in stroke volume for a given reduction in systolic 
pressure (Fig. 2). Thus, one would predict that the largest, 
sickest hearts would be the ones most likely to respond 
favorably to load reduction. In studies of vasodilator therapy 
for congestive heart failure, this phenomenon is well recog- 
nized. For example, Packer et al. (16), observed that the 
beneficial response to hydralazine inpatients with severe heart 
failure was related to ventricular chamber size; it is not unlikely 
that the same would be true for patients with chronic valvular 
regurgitation. A particular benefit of ventricular volume reduc- 
tion in valvular regurgitation is suggested by a study of the 
effect of nitroprusside in patients with severe ischemic ardio- 
myopathy (17). Those patients with clinically relevant mitral 
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Figure 2. Pressure-volume loops and end-systoLic pressure-volume 
relations in a mildly depressed and a myopathic ventricle. In the 
former, ejection fraction is --50%, and the slope of the end-systolic 
pressure-volume relation (Emax) is 2.5. In the latter, ejection fraction 
is -30%, and En, a× is only 1.3. In the case of the myopathic ventricle, 
a given reduction in end-systolic pressure (AP) effects a greater 
reduction i end-systolic volume (AV) than in the mildly depressed 
ventricle. In patients with chronic aortic or mitral regurgitation, the 
salutary hemodynamic effects of vasodilators are most marked in the 
most symptomatic patients with the largest hearts and the most 
depressed systolic function. 
regurgitation had larger ventricles and responded to the vaso- 
dilator with a greater increase in forward cardiac output 
(coincident with a decrease in regurgitant volume) than did 
those without mitral regurgitation. Whether the larger ventri- 
cle or the mitral regurgitation was the major factor esponsible 
for the more favorable response to preload and afterload 
reduction cannot be answered. In either case, a central role for 
reducing LV volume is apparent. 
There are other possible explanations for the benefit of 
vasodilator therapy in chronic volume overload that may be 
particularly relevant o the patient with aortic regurgitation. 
Because the work and power of the normal ventricle is 
maximal at 50% to 60% of peak isometric force (18), and 
because peak systolic stress is characteristically elevated in 
aortic regurgitation (19,20), afterload reduction should enable 
such a volume-overloaded ventricle to perform more work 
merely by moving the work load relation to a more favorable 
and efficient operative load (21,22). A similar effect may be 
seen in severe decompensated mitral regurgitation i which 
systolic loads are elevated. 
In this respect, it is also important to recognize the inter- 
action of preload and afterload reduction. Although relief of 
venous congestion is directly related to preload reduction, the 
associated ecrease in chamber volume effects a secondary 
decrease in afterload through the Laplace relation; such 
unloading is independent of any vasomotor effect on the 
peripheral resistance vessels. In this way, vasodilator therapy 
results in reduced venous congestion, restoration of preload 
reserve and lower systolic wall stress, which provides astimulus 
for regression of hypertrophy and remodeling of a smaller, 
more efficient ventricle (Fig. 1). 
Short-Term Vasodilator Effects 
The hemodynamic effects of short-term administration f 
vasodilators in chronic aortic (23-30) and mitral regurgitation 
(25,31-42) are summarized in Tables 1 and 2. 
Aortic Regurgitation 
In three studies (23-25) of the effects of intravenous 
nitroprusside in patients with chronic aortic regurgitation, the 
hemodynamic responses were quite consistent. Heart rate 
changed little, if at all, and significant reductions in arterial 
pressure, LV end-diastolic pressure and volume and an in- 
crease in the systolic ejection fraction were observed. Cardiac 
index increased in two of the three studies. Examination of 
individual responses uggested that patients with high filling 
pressures, reduced LV systolic function and elevated systolic 
pressures were the most likely to benefit from nitroprusside 
infusion. Sasayama et al. (25) concluded that the beneficial 
effects of combined afterload and preload reduction (i.e., with 
nitroprusside) are most apparent in patients who have ex- 
hausted their preload reserve. In this circumstance, relief of 
venous congestion can be achieved with relatively little yen- 
Table 1. Vasodilators in Aort ic Regurgitation: Short-Term Effects 
No. of BP 
Study (rcf no.) Year Drug Pts HR (D/S) SVR EDV ESV EF RegF RegV FSV CI EDP 
Bolen ct al. (23) 1976 NP 13 0 { / ~ { J' ,l, ], 1' ,1, 
Miller et al. (24) 1976 NP 12 0 ~ / ,~ ,~ ~ " ,~ 0 1" { 
Sasayama et al. (25) 1982 NP 7 { / ~ ,~ T 0 0 0 0 1' 
Greenberg et al. (26) 1981 HDZ 11) ( { ) ,!, { { ]" { ~ ]' " ,~ 
Reske et al. (27) 1985 CAP 10 0 0 /0  0 
Rothlisberger et al. (28) 1993 CAP 10 { ~ / ~ + 0 0 0 0 0 { { 
Fioretti et al. (29) 1982 NIF 12 {/0 { 0 1) 0 0 '[' 
Shen et al. (30) 1984 NIF 20 } ~/0 { 0 0 0 { I' " 
Rothlisberger et al. (28) 1993 NIF 10 0 ],/0 ~ 0 0 0 ,~ " I' ], 
BP blood pressure; CAP = captopril; CI = cardiac index; D - diastolic; EDP = end-diastolic pressure; EDV = end-diastolic volume; EF = ejection fraction; 
ESV - end-systolic volume; FSV forward stroke volume; HDZ = hydralazine; HR = heart rate; NIF nifedipine; NP = nitroprusside; Pts = patients; ref = 
reference; RegF regurgitant fraction; RegV = regurgitant volume; S - systolic; SVR = systemic vascular esistance; 0 - no change; ], - decrease; I' = increase; 
( ~ ) = decrease in mean pressure. 
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Table 2. Vasodilators in Mitral Regurgitation: Short-Term Effects 
No. of BP 
Study (ref no.) Year Drug Pts HR (D/S) SVR EDV ESV EF RegF RegV FSV CI EDP 
Chatterjee t al. (31) 1973 NP 8 ,1, ( ,!, ) ,L $ ,L T ~, ~ I' I' $ 
Goodman et al. (32) 1974 NP 14 0 ( ,!, ) ~, ; ,~ 0 ~, ~ I' I' $ 
Harshaw et al. (33) 1975 NP 7 0 ( ,1, ) ~ 0 0 0 ~ ~ 1' T ,!, 
Sasayama ct al. (25) 1982 NP 5 0 ~ / ; ~ 0 + ~ t 1' ,, 
Greenberg et al. (34) 1978 HDZ l0 0 ( + ) ~ 0 (1 0 ~ ~ 1' 1' 0 
Greenberg et al. (35) 1982 HDZ 16 ~ (0) { T 1' ,, 
Heck et al. (36) 1985 CAP 10 ~ / $ 0 
Wisenbaugh et al. (37) 1992 CAP 9 ], ( ,!, ) 0 0 0 0 0 ,[ 
Rothlisberger et al. (38) 1994 CAP 8 ], + / + 0 0 0 0 0 0 0 0 
Sch6n et al. (39) 1994 QUIN 12 ~ & /+ + & T & & 0 ,, 
Sniderman et al. (40) 1974 NTG 9 0 0/ ~ 0 ~ 0 0 0 
Elkayam et al. (41) 1987 NTG 10 ~ ( ~, ) I) ,~ ~ i' 0 0 0 
Jeang et al. (42) 1986 ISD 7 1' ( + ) 0 ,L 0 0 J, 
Rothlisberger et al. (38) 1994 NIF 8 0 ], / ~, ~ 0 0 0 ~ 0 0 J, 
ISD isosorbidc dinitrate: NTG - nitroglycerin; QUIN - quinapril; other abbreviations and symbols as in Table 1. 
tricular volume change, and the negative heterometric effect 
on systolic function is thus blunted. Similar findings were 
reported by Greenberg et al. (26) after intravenous hydral- 
azine. 
In two studies (27,28) of the effect of a single dose of 
captopril, the results were less consistent than those observed 
with nitroprusside or hydralazine. In neither study was a 
significant change in the ejection fraction observed. The re- 
sponses to a single oral dose of nifedipine (20 rag) in three 
studies (28-30) were for the most part similar. Although there 
was no significant change in LV end-diastolic volume, there 
was a decrease in end-diastolic pressure. Ejection fraction did 
not change, but cardiac index increased in all three studies. 
These data indicate that intravenous nitroprusside is the 
preferred agent for the immediate or short-term treatment of
aortic regurgitation. Hydralazine can produce similar salutary 
results. Nifedipine produces an increase in cardiac index and a 
decrease in end-diastolic pressure (similar to that seen with 
nitroprusside or hydralazine) but has little effect on ventricular 
volume. On the basis of available data, there appears to be 
little rationale for the use of captopril in the short-term 
treatment of patients with aortic regurgitation. 
Mitral Regurgitation 
The major effects of short-term vasodilator therapy in 
patients with chronic mitral regurgitation are summarized in
Table 2. Not apparent from Table 2 is that the pooled patient 
population i  these studies is much more heterogeneous than 
that encountered in studies of chronic aortic regurgitation. I  
some instances, the study group was composed entirely of 
patients with fixed orifice (i.e., rheumatic) mitral regurgitation. 
In others, primary myocardial disease was the etiology of the 
mitral regurgitation, whereas in others the etiology was mixed. 
Nonetheless, a pattern of response is apparent. 
Intravenous nitroprusside (25,31-33) and hydralazine 
(34,35) had similar beneficial effects on forward stroke volume, 
cardiac index and regurgitant flow. There was no significant 
change in ejection fraction. Despite the widespread use of 
ACE inhibitors in patients with congestive heart failure, he- 
modynamic and volumetric data on the effects of these agents 
in chronic mitral regurgitation are relatively sparse and the 
results conflicting (36-39). 
The short-term response to nitrate therapy in chronic mitral 
regurgitation consists of a reduction in LV end-diastolic vol- 
ume but no change in forward or regurgitant flow (40-42). 
These results are most likely confounded by the inclusion of 
patients with fixed orifice and dynamic orifice lesions. Indeed, 
Jeang et al. (42), observed that regurgitant flow increased 72% 
in rheumatic mitral regurgitation a d decreased 5 % in patients 
with nonrheumatic mitral regurgitation after isosorbide dini- 
trate. In mitral valve prolapse, Takenaka et al. (43) found that 
changes in LV size (i.e., degree of prolapse) and pressure 
interact o determine the regurgitant volume. As was seen in 
chronic aortic regurgitation, the most consistent beneficial 
results of short-term vasodilator therapy are seen with the 
administration f nitroprusside. 
Differences in Short-Term Response to 
Vasodilator Therapy 
Although consistent reductions in arterial pressure, sys- 
temic vascular resistance, regurgitant fraction and end- 
diastolic pressure and volume were observed in both mitral and 
aortic regurgitation after nitroprusside, forward stroke volume 
generally increased and ejection fraction remained unchanged 
in mitral regurgitation, whereas ejection fraction generally 
increased and forward stroke volume remained unchanged in
aortic regurgitation. It would appear, therefore, that as a 
consequence of combined preload and afterload reduction 
with nitroprusside, a reciprocal relation between regurgitant 
and forward flow characterizes the response in mitral regurgi- 
tation. By contrast, in aortic regurgitation correction of after- 
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Table 3. Vasodilators in Aortic Regurgitation: Long-Term Effects 
No. of BP 
Study (ref no.) Year Drug Pts HR (D/S) EDV ESV EF RegF EDD ESD FS 
Jensen et al. (44) 1983 HDZ 6 ~' /0 J, l, ~, 
Kleaveland et al. (45) 1986 HDZ 6 0 ~,/0 0 0 0 0 0 ~' 
Greenberg et al. (46) 1988 HDZ 45 0 0/'ll ~ ~, ~' ~, 0 0 0 
Dumesnil et al. (47) 1990 HDZ 7 0 0/0 ~, $ 0 
Lin et al. (48) 1994 HDZ 38 0 ,!, / ,L 0 0 0 
Heck et al. (36) 1985 CAP 17 0 I 
Wisenbaugh et al. (49) 1994 CAP 11 0t0 0 0 0 
Sch6n et al. (48) 1994 QUIN 12 0 1,/0 ~, ~ 0 J, J, ,!, 
Lin et al. (48) 1994 ENAL 38 0 ~, / ~ J~ 0 
Scognamiglio et al. (51) 1990 NIF 38 0 J,/0 ,L 1' 
EDD = end-diastolic dimension; ENAL = enalapril; ESD = end-systolic dimension; FS = fractional shortening; other abbreviations and symbols as in Tables 1 
and 2. 
load mismatch dominates the response, and a decrease in 
preload limits the increase in forward flow. This interpretation 
is supported by the fact that peak systolic stresses are substan- 
tially higher in chronic aortic regurgitation than in mitral 
regurgitation (19); thus, the substrate for afterload reduction 
in chronic aortic regurgitation makes this lesion more suscep- 
tible to favorable manipulation of the inverse force-shortening 
relation than is the case in chronic mitral regurgitation. 
Long-Term Effects of Vasodilator Therapy 
The effects of long-term vasodilator therapy in chronic 
aortic regurgitation (36,44-51) and chronic mitral regurgita- 
tion (36,49,52) are summarized in Tables 3 and 4. 
Aortic Regurgitation 
The results of five hydralazine studies (44-48) are shown in 
Table 3. In the largest randomized, placebo-controlled, 
double-blind trial of hydralazine (average dose 216 rag/day), 
Greenberg et al. (46) observed no significant changes in heart 
rate or blood pressure during drug therapy in 45 largely 
asymptomatic patients followed for up to 24 months. Despite 
this finding, significant and progressive reductions in end- 
diastolic and end-systolic volumes were observed. Similar 
changes were not observed in the 35 patients in the control 
group. Ejection fraction decreased slightly in the placebo 
group, whereas a small increase was observed in hydralazine- 
treated patients. In contrast to these salutary results, Lin et al. 
(48) did not find a salutary effect of this drug despite a 
significant decrease in systolic and diastolic pressures. 
Wisenbaugh et al. (49) observed no effect upon LV dimen- 
sions or ejection fraction after 6 months of captopril therapy in 
23 patients with severe chronic aortic regurgitation. However, 
Sch6n et al. (50) reported significant reductions in LV volume 
and an increase in ejection fraction in 12 patients with chronic 
aortic regurgitation after 1 year of quinapril therapy. Lin et al. 
(48) reported the results of a randomized, double-blind trial 
comparing enalapril and hydralazine therapy in 76 asymptom- 
atic patients with mild to severe chronic aortic regurgitation. 
Arterial pressure decreased in both groups. At 1 year, patients 
receiving enalapril had a significant reduction in LV volume 
and mass, whereas no significant changes were found in the 
hydralazine group (Table 3). 
Scognamiglio et al. (51), studied the effect of long-term 
nifedipine therapy in a randomized, double-blind, placebo- 
controlled trial in 72 asymptomatic patients with severe aortic 
regurgitation. After 12 months of nifedipine therapy (20 mg 
twice daily), significant reductions in LV end-diastolic volume, 
LV mass and LV mean systolic stress and a significant increase 
in ejection fraction were observed. In the placebo group, a 
small but significant decrease inejection fraction was found; no 
changes were observed in the other variables. Except for a 
decrease in systolic blood pressure in the nifedipine group, no 
significant changes in heart rate, diastolic blood pressure or 
cardiothoracic ratio were observed during the trial. In a 
subsequent report, the same investigators (53) followed the 
course of 143 patients with chronic aortic regurgitation and 
normal left ventricular function who were randomized to 
receive either nifedipine (20 mg twice daily) or digoxin 
(0.25 mg daily). After 6 years, a significantly larger proportion 
of the digoxin group had undergone valve replacement, sug- 
Table 4. Vasodilators inMitral Regurgitation: Long-Term Effects 
No. of BP 
Study (ref no.) Year Drug Pts HR (D/S) EDV ESV EF RegF EDD ESD FS 
Heck et al. (36) 1985 CAP 10 0 ,t 
Wisenbaugh et al. (49) 1994 CAP 12 0/0 0 0 0 0 
Sch6n et al. (52) 1994 QUIN 12 ~ ,~ / l, ~ ,~ 0 ~, ~, ~, 0 
Abbreviations and symbols as in Tables 1 to 3. 
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gesting that nifedipine therapy reduces or delays the need for 
aortic valve replacement. 
Mitral Regurgitation 
After studying the short-term effects of hydralazine in 16 
symptomatic patients with severe mitral regurgitation, Green- 
berg et al. (35) followed their clinical course and found that 8 
achieved a sustained symptomatic mprovement over a mean 
follow-up period of 13 months. The remaining eight patients 
either experienced intolerable side effects or failed to experi- 
ence symptomatic mprovement; these patients were treated 
surgically. Heck et al. (36), treated 10 patients with captopril 
for 3 to 5 months and found a reduction in the regurgitant 
fraction. Sch6n et al. (52) studied the effect of quinapril in 12 
symptomatic patients with chronic mitral regurgitation of 
mixed etiologies. After 1 year, there was a reduction in LV 
end-diastolic volume and regurgitant volume, and hemody- 
namic variables during exercise were improved. Wisenbaugh et 
al. (49) compared the effects of captopril versus placebo in 32 
asymptomatic patients with chronic mitral regurgitation; most 
had rheumatic disease. After 6 months, there was no difference 
in arterial pressure, LV volume or ejection fraction between 
the two groups. 
The different results in these latter two studies may be due 
in part to the fact that Sch6n et al. (52) studied patients who 
were more symptomatic and had slightly larger hearts than 
those treated by Wisenbaugh et al. (49). Moreover, the pa- 
tients in the study by Sch6n et al. exhibited higher baseline 
arterial pressures that decreased significantly during treat- 
ment. By contrast, the patients in the study by Wisenbaugh et 
al. had lower arterial pressures that did not change during 
treatment. Certainly, vasodilator therapy provides the most 
benefit in patients with the largest hearts, the poorest systolic 
function and the most disabling symptoms (35). Some benefit 
can be seen in less symptomatic patients with only moderate 
LV enlargement, but there appears to be no detectable benefit 
in asymptomatic patients with only minimal LV enlargement 
(49,52). 
Discussion 
The specific effects of vasodilators on regurgitant fraction, 
ejection fraction and forward flow depend on the nature of the 
regurgitant lesion, its etiology and the hemodynamic determi- 
nants of regurgitant flow. These determinants include the 
magnitude and duration of the pressure gradient across the 
valve and the effective orifice area. 
The most consistent hemodynamic effect of vasodilator 
therapy in patients with chronic LV volume overload (both 
aortic and mitral regurgitation) is a reduction in ventricular 
filling pressures. This effect is observed not only with agents 
that reduce venous tone but also with vasoactive drugs that act 
primarily on the arterial resistance vessels (i.e., hydralazine 
and nifedipine). Although most vasodilators also produce a 
reduction in ventricular volume, this effect has been observed 
less consistently than the decrease in filling pressures, perhaps 
due to less accuracy in the volume measurements or to the 
steep operative portion of the diastolic pressure-volume rela- 
tion in symptomatic patients with LV volume overload. 
Specific changes in ejection fraction and regurgitant volume 
appear to depend importantly on the clinical substrate under 
study. That is, the response to combined preload and afterload 
reduction and, to a lesser extent, to all vasodilator therapy is 
different in patients with chronic aortic regurgitation than in 
those with chronic mitral regurgitation. For example, in aortic 
regurgitation, itroprusside consistently effects a decrease in 
end-diastolic volume and an increase in ejection fraction; 
changes in regurgitant volume and forward stroke volume are 
less consistent. By contrast, in mitral regurgitation, itroprus- 
side invariably reduces regurgitant volume and increases for- 
ward stroke volume, whereas ejection fraction generally does 
not change. These observations suggest hat the reciprocal 
relation between forward stroke volume and regurgitant vol- 
ume in chronic mitral regurgitation is favorably influenced by 
ventricular volume reduction and a decrease in the mitral 
regurgitant orifice area, whereas the major benefit of vasodi- 
lator therapy in chronic aortic regurgitation is brought about 
by a reduction in the high levels of systolic stress that charac- 
terize this lesion. This reduction in afterload effects an increase 
in ejection fraction despite a decrease in preload. 
The disappointing responses to single-dose ACE inhibitors 
reported in both chronic aortic regurgitation (27,28) and 
chronic mitral regurgitation (36-38) warrant special comment. 
In chronic mitral regurgitation, Wisenbaugh et al. (37) suggests 
that this lack of a favorable response isdue to inhibition of the 
positive inotropic effect of angiotensin II. A decrease in heart 
rate may also contribute to the lack of improvement in cardiac 
index after single-dose ACE inhibitor therapy in aortic and 
mitral regurgitation. The failure of captopril to decrease LV 
dimensions and regurgitant fraction in the patients from South 
Africa with chronic mitral regurgitation (37,38) may be due in 
large part to the fact that most of the subjects tudied had fixed 
orifice (rheumatic) mitral regurgitation. This distinction is 
especially important with the use of venodilators (nitrates) 
because the regurgitant volume may increase in rheumatic 
mitral regurgitation after nitrate administration (42). This 
increase may occur in mitral regurgitation associated with 
hypertrophic cardiomyopathy or mitral valve prolapse, but the 
reverse is generally observed in patients with papillary muscle 
dysfunction, dilated cardiomyopathy or coronary heart disease. 
The results of long-term therapy with vasodilators in some 
respects are more impressive than those predicted by studies of 
single-dose drug administration. In chronic aortic regurgita- 
tion, significant reductions in ventricular volumes have been 
observed after chronic therapy with hydralazine (46), nifedi- 
pine (51), enalapril (48) and quinapril (50). Excluding patients 
with fixed orifice mitral regurgitation, long-term therapy with 
captopril (36) and with quinapril (52) has reduced regurgitant 
fraction in patients with chronic mitral regurgitation; in the 
latter instance, ventricular volumes were also measured and 
decreased significantly. The demonstration that long-term 
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vasodilator therapy can decrease systolic wall stress and LV 
mass in patients with chronic volume overload (48,50,51,52) 
has further contributed to enthusiasm for the use of these 
drugs. 
Conclusions 
The choice of long-term vasodilator therapy in patients with 
chronic aortic or mitral regurgitation remains problematic. In 
chronic aortic regurgitation, convincing beneficial effects have 
been shown with nifedipine, ACE inhibitors and hydralazine. 
However, long-term hydralazine therapy is often poorly toler- 
ated and, in one randomized study (48), was shown to be less 
effective than enalapril. A direct comparison of nifedipine 
(using a 24-h drug delivery system) and an ACE inhibitor 
would be both timely and appropriate. 
For most patients with chronic mitral regurgitation, there is 
reason to believe that preload reduction is an important 
ingredient in mediating the benefit of vasodilator therapy. 
Thus, by reducing the effective regurgitant orifice area, a 
decrease in regurgitant volume can be achieved. A reduction in 
arterial pressure (i.e., LV systolic pressure) may also contrib- 
ute to this salutary effect, especially if the patient is hyperten- 
sive. This latter mechanism is of primary importance in fixed 
orifice rheumatic mitral regurgitation. The available data, 
although very limited, support he use of an ACE inhibitor as 
the vasodilator of choice for most patients with symptomatic 
mitral regurgitation. It should be recognized that there are no 
published studies that support the use of oral vasodilator 
therapy in asymptomatic patients with chronic mitral regurgi- 
tation. 
We are indebted to Pare Amico for assistance in the preparation of the 
manuscript. 
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